Showing results (91-100 of 144) with videos related to
Sort By:
Pageof 15
Folia Histochemica Et Cytobiologica|December 10, 2009
NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinomaMarek Olakowski, Tomasz Tyszkiewicz, Michał Jarzab, et al.Frontiers in Neurology|December 12, 2019
The Association of SNPs Located in the CDKN2B-AS1 and LPA Genes With Carotid Artery Stenosis and Atherogenic StrokeAnetta Lasek-Bal, Dorota Kula, Tomasz Urbanek, et al.European Journal of Endocrinology|November 13, 2004
Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practiceMartin Schlumberger, Furio Pacini, Wilmar M Wiersinga, et al.Plos One|December 2, 2015
BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid CarcinomaDagmara Rusinek, Michal Swierniak, Ewa Chmielik, et al.Endokrynologia Polska|July 4, 2006
[Gene expression analysis by DNA microarray in papillary thyroid cancer]Elzbieta Gubała, Małgorzata Wiench, Małgorzata Oczko-Wojciechowska, et al.Healthcare (Basel, Switzerland)|September 23, 2022
Tackling Thyroid Cancer in Europe-The Challenges and OpportunitiesDenis Horgan, Dagmar Führer-Sakel, Paula Soares, et al.Hybridoma (2005)|June 27, 2006
Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumorsZbigniew Wygoda, Dorota Kula, Grazyna Bierzyńska-Macyszyn, et al.Proceedings of the National Academy of Sciences of the United States of America|October 13, 2010
Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytomaSara Molatore, Sandya Liyanarachchi, Martin Irmler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialSamuel A Wells, Bruce G Robinson, Robert F Gagel, et al.Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.Pageof 15